Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
diabetes mellitus 6 endocrinologydiseases
obesity 2 endocrinologydiseases
sitagliptin 3 endocrinologydiseasesdrugs
Insulin 3 endocrinologydiseasesdrugs
Liraglutide 1 endocrinologydiseasesdrugs
dapagliflozin 2 endocrinologydiseasesdrugs
diabetic ketoacidosis 3 endocrinologydiseases
metformin 5 endocrinologydiseasesdrugs
pioglitazone 2 endocrinologydiseasesdrugs
type 1 diabetes mellitus 1 endocrinologydiseases
type 2 diabetes mellitus 5 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Insulin 15791 resistance has been shown to develop in target tissues, including liver, adipose, muscle and myocardium. Insulin resistance is a major driver of adverse cardiovascular outcomes that acts synergistically with hyperglycaemia
Insulin 16408 treatment improves both fasting and postprandial measures of beta‐cell function and insulin secretion.37 Insulin secretion rate was significantly increased with canagliflozin compared with baseline at all plasma glucose
Insulin 16635 concentrations (7‐16 mmol/L); these increases were of similar magnitude with canagliflozin vs sitagliptin.37 Insulin sensitivity, measured using the oral glucose insulin sensitivity index corrected for UGE, also improved
Liraglutide 4975 empagliflozin treatment was associated with slower progression of kidney disease compared with placebo.7 In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial in patients
dapagliflozin 29007 inhibitors in patients with T2DM, Tang and colleagues found that all evaluated drugs (canagliflozin, dapagliflozin , empagliflozin and ipragliflozin) were associated with modest increases in serum magnesium levels ranging
dapagliflozin 35109 of fracture (ie, upper extremity) observations have been made in studies with empagliflozin106 and dapagliflozin 101 in high‐risk individuals with T2DM, suggesting that an increased risk of fractures may be a class
metformin 12749 significant, dose‐dependent reductions in HbA1c, both as monotherapy and as part of combination therapy with metformin ± a sulphonylurea for up to 104 weeks.11 In active‐controlled Phase 3 studies, canagliflozin 300 mg
metformin 14604 hypoglycaemia.11 A post hoc analysis of data from a Phase 3 study in patients with T2DM inadequately controlled on metformin showed that a higher proportion of patients achieved their glycaemic goals (ie, HbA1c <7% or <6.5%)
metformin 16228 lesions.36Analysis of data from three Phase 3 studies of canagliflozin as monotherapy and as add‐on to metformin plus sulphonylurea showed that 6‐12 months of canagliflozin treatment improves both fasting and postprandial
metformin 19038 measurements from a Phase 3 study of canagliflozin in patients with T2DM inadequately controlled on metformin showed a mean change in visceral adipose tissue of −7.3% with canagliflozin 100 mg, −8.1% with
metformin 24046 post hoc analysis of results from a Phase 3 study in patients with T2DM inadequately controlled on metformin showed that canagliflozin treatment slowed the progressive decline in eGFR and lowered the ACR compared
pioglitazone 17143 alone.5, 38 In a rodent model, Watanabe and colleagues showed that the combination of canagliflozin with pioglitazone reduced hyperinsulinaemia and improved whole‐body insulin sensitivity compared with pioglitazone monotherapy.39
pioglitazone 17242 pioglitazone reduced hyperinsulinaemia and improved whole‐body insulin sensitivity compared with pioglitazone monotherapy.39 Further studies are needed to confirm whether indirect improvement in insulin sensitivity
sitagliptin 12936 studies, canagliflozin 300 mg provided greater reductions in HbA1c compared with both glimepiride and sitagliptin .11In addition to reducing HbA1c levels, the increase in UGE that occurs with canagliflozin treatment
sitagliptin 16620 glucose concentrations (7‐16 mmol/L); these increases were of similar magnitude with canagliflozin vs sitagliptin .37 Insulin sensitivity, measured using the oral glucose insulin sensitivity index corrected for UGE,
sitagliptin 25770 baseline to Week 52 with canagliflozin treatment and was not different at Week 52 with canagliflozin vs sitagliptin .70 In contrast to results in patients with T2DM who have normal or mild renal impairment, reductions
Select Disease Character Offset Disease Term Instance
diabetes mellitus 129 of Clinical PracticeEffects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus Matthew J. BudoffJohn P. H. Wilding1Division of CardiologyLos Angeles Biomedical Research InstituteTorranceCAUSA2Obesity
diabetes mellitus 571 aimsCardiovascular disease is the most common cause of morbidity and mortality among people with type 2 diabetes mellitus (T2DM). The main contributors to cardiovascular risk in T2DM are chronic hyperglycaemia, reduced insulin
diabetes mellitus 2200 treatment.BudoffMJ, WildingJPH. Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus . Int J Clin Pract. 2017;71:e12948https://doi.org/10.1111/ijcp.12948.Review criteriaStructured searches
diabetes mellitus 3461 million deaths each year. It has been estimated that up to 91% of people with diabetes have type 2 diabetes mellitus (T2DM).1 Cardiovascular disease (CVD) is a serious complication of T2DM, contributing to the majority
diabetes mellitus 11338 low‐density lipoprotein cholesterol; SGLT2i, sodium glucose co‐transporter 2 inhibitors; T2DM, type 2 diabetes mellitus . aArrows indicate the direction of statistically significant changes associated with canagliflozin treatment.John
diabetes mellitus 22465 renin‐angiotensin system.58 Empagliflozin has been shown to reduce arterial stiffness in patients with type 1 diabetes mellitus , and it has been speculated that SGLT2 inhibitors may improve endothelial function or the elastic properties
diabetic ketoacidosis 36734 safety assessments will be possible using the final study results.Concerns about an increased risk of diabetic ketoacidosis have been reported with all marketed SGLT2 inhibitors. The overall incidence of serious AEs of diabetic
diabetic ketoacidosis 36851 ketoacidosis have been reported with all marketed SGLT2 inhibitors. The overall incidence of serious AEs of diabetic ketoacidosis was generally low across randomised controlled trials of canagliflozin (4/5337 [0.07%] with canagliflozin
diabetic ketoacidosis 37109 canagliflozin 300 mg, and 2/6909 [0.03%] with comparators) and consistent with the observed rate of diabetic ketoacidosis in the general population of patients with T2DM and in patients treated with other SGLT2 inhibitors.108,
obesity 781 reduced insulin sensitivity, hypertension and dyslipidaemia. Other cardiovascular risk factors include obesity and visceral adiposity, increased arterial stiffness and renal dysfunction. Results from clinical trials,
obesity 3870 contributors to an increased risk of CVD in people with T2DM. Other contributors to this risk may include obesity , especially visceral adiposity, increased arterial stiffness and renal dysfunction.5Recent findings
type 1 diabetes mellitus 22458 renin‐angiotensin system.58 Empagliflozin has been shown to reduce arterial stiffness in patients with type 1 diabetes mellitus , and it has been speculated that SGLT2 inhibitors may improve endothelial function or the elastic properties
type 2 diabetes mellitus 122 Journal of Clinical PracticeEffects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus Matthew J. BudoffJohn P. H. Wilding1Division of CardiologyLos Angeles Biomedical Research InstituteTorranceCAUSA2Obesity
type 2 diabetes mellitus 564 and aimsCardiovascular disease is the most common cause of morbidity and mortality among people with type 2 diabetes mellitus (T2DM). The main contributors to cardiovascular risk in T2DM are chronic hyperglycaemia, reduced insulin
type 2 diabetes mellitus 2193 treatment.BudoffMJ, WildingJPH. Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus . Int J Clin Pract. 2017;71:e12948https://doi.org/10.1111/ijcp.12948.Review criteriaStructured searches
type 2 diabetes mellitus 3454 to five million deaths each year. It has been estimated that up to 91% of people with diabetes have type 2 diabetes mellitus (T2DM).1 Cardiovascular disease (CVD) is a serious complication of T2DM, contributing to the majority
type 2 diabetes mellitus 11331 low‐density lipoprotein cholesterol; SGLT2i, sodium glucose co‐transporter 2 inhibitors; T2DM, type 2 diabetes mellitus . aArrows indicate the direction of statistically significant changes associated with canagliflozin treatment.John

You must be authorized to submit a review.